Literature DB >> 19272549

Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury.

Sean M Bagshaw1, Shigehiko Uchino, Rinaldo Bellomo, Hiroshi Morimatsu, Stanislao Morgera, Miet Schetz, Ian Tan, Catherine Bouman, Ettiene Macedo, Noel Gibney, Ashita Tolwani, Heleen M Oudemans-van Straaten, Claudio Ronco, John A Kellum.   

Abstract

PURPOSE: The aim of this study is to evaluate the relationship between timing of renal replacement therapy (RRT) in severe acute kidney injury and clinical outcomes.
METHODS: This was a prospective multicenter observational study conducted at 54 intensive care units (ICUs) in 23 countries enrolling 1238 patients.
RESULTS: Timing of RRT was stratified into "early" and "late" by median urea and creatinine at the time RRT was started. Timing was also categorized temporally from ICU admission into early (<2 days), delayed (2-5 days), and late (>5 days). Renal replacement therapy timing by serum urea showed no significant difference in crude (63.4% for urea <or=24.2 mmol/L vs 61.4% for urea >24.2 mmol/L; odds ratio [OR], 0.92; 95% confidence interval [CI], 0.73-1.15; P = .48) or covariate-adjusted mortality (OR, 1.25; 95% CI, 0.91-1.70; P = .16). When stratified by creatinine, late RRT was associated with lower crude (53.4% for creatinine >309 micromol/L vs 71.4% for creatinine <or=309 micromol/L; OR, 0.46; 95% CI, 0.36-0.58; P < .0001) and covariate-adjusted mortality (OR, 0.51; 95% CI, 0.37-0.69; P < .001). However, for timing relative to ICU admission, late RRT was associated with greater crude (72.8% vs 62.3% vs 59%, P < .001) and covariate-adjusted mortality (OR, 1.95; 95% CI, 1.30-2.92; P = .001). Overall, late RRT was associated with a longer duration of RRT and stay in hospital and greater dialysis dependence.
CONCLUSION: Timing of RRT, a potentially modifiable factor, might exert an important influence on patient survival. However, this largely depended on its definition. Late RRT (days from admission) was associated with a longer duration of RRT, longer hospital stay, and higher dialysis dependence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19272549     DOI: 10.1016/j.jcrc.2007.12.017

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  91 in total

Review 1.  Continuous renal replacement therapy: recent advances and future research.

Authors:  John R Prowle; Rinaldo Bellomo
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

2.  Application of continuous renal replacement therapy for acute kidney injury in elderly patients.

Authors:  Sheng Liu; Qing-Li Cheng; Xiao-Ying Zhang; Qiang Ma; Yu-Ling Liu; Rong Pan; Xiao-Yan Cai
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version : JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Clin Exp Nephrol       Date:  2013-08       Impact factor: 2.801

4.  Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version. JSN, JRS, and JCS Joint Working Group.

Authors:  Iwao Ohno; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Naoki Kashihara; Hirokazu Okada; Yasuhiro Komatsu; Shozo Tamura; Kazuo Awai; Yasuyuki Yamashita; Ryohei Kuwatsuru; Atsushi Hirayama; Yoshihiko Saito; Toyoaki Murohara; Nagara Tamaki; Akira Sato; Tadateru Takayama; Enyu Imai; Yoshinari Yasuda; Daisuke Koya; Yoshiharu Tsubakihara; Shigeo Horie; Yukunori Korogi; Yoshifumi Narumi; Katsumi Hayakawa; Hiroyuki Daida; Koichi Node; Isao Kubota
Journal:  Jpn J Radiol       Date:  2013-08       Impact factor: 2.374

5.  Dialysis versus nondialysis in patients with AKI: a propensity-matched cohort study.

Authors:  F Perry Wilson; Wei Yang; Carlos A Machado; Laura H Mariani; Yuliya Borovskiy; Jeffrey S Berns; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

6.  Continuous renal replacement therapy with a polymethyl methacrylate membrane hemofilter suppresses inflammation in patients after open-heart surgery with cardiopulmonary bypass.

Authors:  Hiroshi Mukaida; Satoshi Matsushita; Takahiro Inotani; Atsushi Nakamura; Atsushi Amano
Journal:  J Artif Organs       Date:  2018-02-05       Impact factor: 1.731

7.  Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury.

Authors:  Ron Wald; Neill K J Adhikari; Orla M Smith; Matthew A Weir; Karen Pope; Ashley Cohen; Kevin Thorpe; Lauralyn McIntyre; Francois Lamontagne; Mark Soth; Margaret Herridge; Stephen Lapinsky; Edward Clark; Amit X Garg; Swapnil Hiremath; David Klein; C David Mazer; Robert M A Richardson; M Elizabeth Wilcox; Jan O Friedrich; Karen E A Burns; Sean M Bagshaw
Journal:  Kidney Int       Date:  2015-07-08       Impact factor: 10.612

Review 8.  Fluid balance and acute kidney injury.

Authors:  John R Prowle; Jorge E Echeverri; E Valentina Ligabo; Claudio Ronco; Rinaldo Bellomo
Journal:  Nat Rev Nephrol       Date:  2009-12-22       Impact factor: 28.314

9.  Clinical Features and Indications Associated with Mortality in Continuous Renal Replacement Therapy for Pediatric Patients.

Authors:  Guntulu Sık; Asuman Demirbuga; Seda Günhar; Kemal Nisli; Agop Citak
Journal:  Indian J Pediatr       Date:  2019-02-11       Impact factor: 1.967

10.  Fluid balance as a biomarker: impact of fluid overload on outcome in critically ill patients with acute kidney injury.

Authors:  Sean M Bagshaw; Patrick D Brophy; Dinna Cruz; Claudio Ronco
Journal:  Crit Care       Date:  2008-07-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.